PS2: ATMP innovations and clinical trials with genetically modified organisms


Patrick Ginty focused on ‘off-the-shelf’ cell therapies from a scientific and regulatory perspective. He stressed the importance of defining the criteria, namely, cell-based therapies that are manufactured from healthy allogeneic donor with material and stored until ready for patient administration – essentially one donor to multiple recipients with no patient-donor specificity required. Conversely, we then don’t include autologous cell therapies (same donor and recipient) and allogeneic cell therapies which are donor-recipient specific, ie., anything which is Human Leucocyte Antigen-restricted (HLA) to avoid immune reaction.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.


Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!